Enyo Pharma competitors & alternatives

XORTX Therapeutics Inc.XRTX · BiotechnologyCalgary, Canada

71% matchPublic

Biotechnology

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.

Biotechnology

Amolyt Pharma is a biotechnology company focused on developing peptide therapeutics for rare endocrine and metabolic diseases. Its lead program, eneboparatide, is being developed for chronic hypoparathyroidism, serving patients with serious hormone-related disorders and the clinicians who treat them.

R1 TherapeuticsLife SciencesUnited States

70% match

Life Sciences

R1 Therapeutics is a renal-focused biotech company developing innovative, first-in-class, category-defining therapeutics for patients with kidney disease. Headquartered in San Francisco with additional offices in San Diego and Raleigh, the company started with lead asset AP306.

Unicycive Therapeutics, Inc.UNCY · BiotechLos Altos, United States

68% matchPublic

Similar biotech company

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Similar biotech company

Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.

ZyVersa Therapeutics, Inc.ZVSA · BiotechWeston, United States

68% matchPublic

Similar biotech company

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Centaurus Therapeutics, Inc.BiotechnologyUnited States

67% matchPrivate

Biotechnology

Centaurus Therapeutics is a clinical-stage biotechnology company that develops first-in-class small-molecule therapies targeting ceramides to treat cardio-kidney-metabolic (CKM) diseases. The company's lead oral asset, CNT2130, inhibits DES1 to reduce excess ceramide production and restore lipid balance for patients suffering from organ decline.

UltragenyxBiotechJapan

66% matchAI 8/100 ▲Green 5/100 ▲

Similar biotech company

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Endeavor Biomedicines, Inc.BiotechnologyUnited States

66% matchPrivate

Biotechnology

Endeavor BioMedicines, Inc. is a San Diego-based biotechnology company focused on developing novel treatments for conditions such as fibrosis.

Similar biotech company

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

KerosBiotechUnited States

66% matchPrivateAI 0/100 ▼Green 0/100

Similar biotech company

Keros Therapeutics is a clinical-stage biopharmaceutical company that develops novel therapeutics targeting the transforming growth factor-beta (TGF-ß) superfamily of proteins. The company focuses on creating treatments for patients with hematological and neuromuscular disorders linked to dysfunctional protein signaling.

Biotechnology

Chinook Therapeutics was a U.S. biotechnology company focused on developing precision medicines for kidney diseases, including IgA nephropathy and other immune-mediated renal conditions. Its programs served patients with serious kidney disorders and the healthcare providers treating them; Novartis acquired Chinook Therapeutics in 2023.